UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150) (see article here).
Pfizer seeks leave in pregabalin section 8 case
As previously reported, the Federal Court of Appeal (FCA) dismissed Pfizer’s appeal from a decision granting Pharmascience’s motion for a summary trial on Pfizer’s defence of ex turpi causa in an action for section 8 damages related to pregabalin (LYRICA). The FCA rejected Pfizer’s arguments and held that infringement was not a viable defence where the patentee did not bring an infringement action in the real world. On April 27, 2020, Pfizer applied to the Supreme Court of Canada for leave to appeal (Docket no. 39150).
Apotex seeks leave to appeal perindopril accounting of profits decision
As previously reported, the FCA dismissed Apotex’s appeal from a decision ordering it to pay over $61M in profits to the Plaintiffs ADIR and Servier for infringement of ADIR’s perindopril patent. The FCA found that the Federal Court made no palpable and overriding error in holding that Apotex would not have used a non-infringing alternative from third-party manufacturers. On May 11, 2020, Apotex applied to the Supreme Court of Canada for leave to appeal (Docket no. 39172).
Supreme Court denies leave in bortezomib section 8 case
On May 7, 2020, the Supreme Court of Canada denied leave to Millennium Pharmaceuticals and Janssen (Docket No. 39007) with respect to a decision affirming Teva’s claim for compensation under section 8 of the Patented Medicines (Notice of Compliance) Regulations. The FCA upheld Justice Locke’s decision finding that Teva would not have infringed two patents because their relevant claims were invalid for obviousness (as previously reported).
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.